论文部分内容阅读
目的研究多西他赛联合mFOLFOX方案化疗治疗进展期胃癌的疗效及其毒副作用。方法31例患者应用该方案起止时间为2005年6月至2007年3月。化疗方案:多西他赛60mg/m2,d1,滴注;OXA130mg/m2,d2,滴注;5-Fu2.8g/m2,civ,46h;CF300mg,d2,5-Fu前2h滴注,每3周为1周期,至少应用2周期。观察应用该方案肿瘤缓解情况及化疗的毒副反应。结果CR3例(9.7%),PR12例(38.7%),SD8例(25.8%),PD8例(25.8%),有效率48.4%。主要不良反应为骨髓抑制、外周神经毒性、脱发。无治疗相关性死亡。结论多西他赛联合mFOLFOX方案治疗进展期胃癌近期疗效较好,药物毒副作用可耐受。
Objective To study the efficacy and side effects of docetaxel combined with mFOLFOX regimen in the treatment of advanced gastric cancer. Methods 31 patients with the program starting and ending time for the June 2005 to March 2007. Chemotherapy program: docetaxel 60mg / m2, d1, drip; OXA130mg / m2, d2, drip; 5-Fu2.8g / m2, civ, 46h; 3 weeks for 1 cycle, at least 2 cycles. Observe the application of the program of tumor response and chemotherapy side effects. Results CR3 (9.7%), PR12 (38.7%), SD8 (25.8%), and PD8 (25.8%) had an effective rate of 48.4%. The main adverse reactions were myelosuppression, peripheral neurotoxicity and hair loss. No treatment-related deaths. Conclusion Docetaxel combined with mFOLFOX regimen is effective in the treatment of advanced gastric cancer in the near future. Drug toxicity can be tolerated.